Emergent BioSolutions Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on May 4, 2011, covering events occurring on April 28, 2011. The filing details a material definitive agreement entered into by Emergent BioDefense Operations Lansing LLC, a wholly-owned subsidiary of the registrant.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The only specific financial value disclosed relates to the new contract modification:
- Contract Value: Up to approximately $101 million.
- Product: BioThrax (Anthrax Vaccine Adsorbed).
- Quantity: Additional 3.42 million doses.
Material Changes
The primary material change is the modification of an existing procurement contract with the Centers for Disease Control and Prevention (CDC). This agreement adds 3.42 million doses to the original contract for 14.5 million doses. Delivery of the additional doses is scheduled to commence immediately following the early completion of the original contract's final delivery.
Outlook, Risks, and Management Commentary
The contract modification includes an option for the CDC to increase the quantity of doses at any time during the performance period. If exercised, additional doses would be supplied at the unit pricing specified for the 3.42 million doses, with delivery continuing at the same rate as the modification. The filing incorporates a press release dated May 2, 2011, by reference for further details. No specific risks or contingencies regarding this agreement are detailed in the text provided.
Investor Verification Checklist
- Verify the exact unit pricing for the additional 3.42 million doses to confirm the $101 million valuation.
- Confirm the timeline for the "early completion" of the original 14.5 million dose delivery to estimate revenue recognition timing.
- Review the attached press release (Exhibit 99.1) for additional context on the CDC's potential exercise of the option to increase quantities.
- Assess the impact of this contract on the company's overall backlog and future cash flow projections.